Results 191 to 200 of about 18,687 (213)

Darunavir/tenofovir

Reactions Weekly, 2018
openaire   +1 more source

Darunavir/ritonavir

Reactions Weekly, 2019
openaire   +2 more sources

Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients

Clinical Pharmacokinetics, 2013
José Moltó, George Xinarianos, Sudeep Pushpakom   +2 more
exaly  

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy

HIV Medicine, 2012
Philippe Flandre, L Cuzin
exaly  

Darunavir/dolutegravir

Reactions Weekly, 2019
openaire   +1 more source

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

Bioorganic and Medicinal Chemistry, 2007
Arun K Ghosh, Hiroaki Mitsuya
exaly  

Darunavir/ritonavir

Reactions Weekly, 2013
openaire   +2 more sources

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Lancet, The, 2007
Bonaventura Clotet, Jean-Christophe Goffard, Adriano Lazzarin   +2 more
exaly  

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

Journal of Antimicrobial Chemotherapy, 2012
André Cabie, L Cuzin, Philippe Flandre   +2 more
exaly  

The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV-Negative Healthy Volunteers

Journal of Clinical Pharmacology, 2007
exaly